Boston Scientific's $1.5B bet on MiRus and Hark's $700M Series A headlined a week of major U.S. venture deals spanning medtech, AI, and aerospace.
A $1.5 billion corporate round for a Georgia orthopedic implant maker topped last week's U.S. venture activity, placing physical tech alongside software artificial intelligence as the week's biggest capital magnets.
MiRus, based in Marietta, Georgia, closed the financing with Boston Scientific as strategic lead. The deal hands Boston Scientific a 34% equity stake and brings MiRus's total raised to $1.6 billion. The company develops implants and treatment systems for musculoskeletal disorders -- a field where artificial intelligence in medicine is increasingly embedded in diagnostics and surgical planning.
Second was Hark, a one-year-old San Jose startup that raised $700 million in a Series A. Parkway Venture Capital led; also in were Nvidia, Intel Capital, AMD, Qualcomm Ventures, ARK Investment Management, Prime Movers Lab, Salesforce Ventures, and Align Ventures. The company says it is building "advanced personalized intelligence and next-generation hardware," with a product planned for summer 2026. No specifics have been disclosed.
The chip pile-on
Four semiconductor companies in the same early-stage cap table is unusual. Nvidia, Intel, AMD, and Qualcomm competing in one round suggests Hark may be developing device-level or silicon integrations relevant to all four firms. Alternatively, it reflects the kind of competitive pile-on that marks peak AI cycle moments. The actual product, expected this summer, will clarify which interpretation holds.
Crunchbase reports that New York-based Modal Labs closed a $355 million Series C led by General Catalyst and Redpoint, focused on AI infrastructure and developer tools. Beyond those top three, the week's list spanned aerospace and defense, fintech, and retail technology -- a distribution that argues against any single-sector narrative.
Broader context
Boston Scientific's 34% stake in MiRus follows medtech's established playbook: invest strategically, integrate clinically, acquire when traction warrants a premium. That structure differs from venture-fund logic, and the $1.5 billion figure -- larger than most Series C rounds for pure-software AI companies -- reflects the capital intensity of FDA-regulated device development.
Hark's round is harder to benchmark. A $700 million Series A for a pre-product company would have been extraordinary in 2023; today it fits a range defined by other pre-revenue AI hardware bets. Context matters: Digital Watch Observatory noted that OpenAI's January rollout of its $8-per-month ChatGPT Go subscription represents the industry's clearest push yet toward sustainable AI monetization -- a question every highly-valued startup will eventually face. Hark has not disclosed a revenue model.
On the product front, the landscape is reshuffling fast. International Business Times reported this week that Google launched Gemini Omni, a multimodal creation model capable of generating content from text, image, audio, and video inputs. The launch targets users left without an alternative after OpenAI discontinued Sora's web and app experiences in April. That kind of rapid turnover at the frontier is the market Hark will enter this summer.
Capital in this cycle is distributing broadly -- orthopedic hardware, edge AI gadgets, cloud infrastructure, aerospace -- rather than concentrating in any single layer. If MiRus's Boston Scientific partnership converts to acquisition, and if Hark ships something credible, the week's two largest deals will have validated very different theses. Investors are betting on both.
Frequently asked questions
What does MiRus make?
MiRus develops implants and treatment systems for musculoskeletal conditions, including orthopedic and spinal devices. The Marietta, Georgia-based company has now raised $1.6 billion in total, with Crunchbase tracking Boston Scientific as its largest investor following this round.
What is Hark building?
Hark describes itself as developing "advanced personalized intelligence and next-generation hardware." The San Jose startup raised $700 million in its Series A but has not publicly described a specific product. A launch is expected in summer 2026.
Why did four chip companies invest in the same AI startup?
Nvidia, Intel Capital, AMD, and Qualcomm Ventures all joined Hark's Series A, which is rare for a pre-product company. It may indicate that Hark is developing hardware with implications across the chip supply chain, though the company has confirmed no technical details.
What happened to OpenAI's Sora video platform?
OpenAI discontinued Sora's web and app access in April 2026, with API access set to end in September. Google responded by launching Gemini Omni, positioning it as a multimodal alternative for developers and creators who relied on Sora.